FBXW7 mutation
Showing 26 - 50 of 4,569
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation Trial in Worldwide (BIIB067)
Active, not recruiting
- ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
-
Phoenix, Arizona
- +29 more
Sep 2, 2021
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Olaparib
- +13 more
-
Edmonton, Alberta, Canada
- +9 more
Jan 9, 2023
Triple Negative Breast Tumors Trial in Worldwide (alpelisib, , nab-paclitaxel)
Active, not recruiting
- Triple Negative Breast Neoplasms
- alpelisib
- +2 more
-
Los Alamitos, California
- +154 more
Jan 12, 2023
NSCLC, Colorectal Cancer, Advanced Solid Tumors Trial in Worldwide (GDC-6036, Atezolizumab, Cetuximab)
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
- GDC-6036
- +6 more
-
Duarte, California
- +68 more
Jan 10, 2023
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
Completed
- Chronic Phase Chronic Myelogenous Leukemia
- +3 more
-
Limerick, Dooradoyle, Ireland
- +32 more
Aug 13, 2021
KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
Active, not recruiting
- KRAS Gene Mutation
- +3 more
- Pembrolizumab
- Trametinib
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Nov 1, 2021
Advanced NSCLC, Metastatic NSCLC Trial in Worldwide (MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab)
Recruiting
- Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
- MRTX849 Monotherapy
- +2 more
-
Prescott Valley, Arizona
- +134 more
Jan 25, 2023
BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma Trial in United States
Recruiting
- BRAF V600E Negative
- +12 more
- Cetuximab
- +3 more
-
Scottsdale, Arizona
- +15 more
Aug 23, 2022
Centralized Tumour Board and Secondary Intervention Rate in mCRC
Not yet recruiting
- Metastatic Colorectal Cancer
- +3 more
- Virtual centralized multidisciplinary tumour board
- (no location specified)
Apr 15, 2021
Tumors, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Worldwide (niraparib,
Completed
- Neoplasms, Breast
- +5 more
- niraparib
- Physician's choice
-
Tucson, Arizona
- +103 more
Nov 2, 2021
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
-
Los Angeles, California
- +110 more
Jan 26, 2023
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11
Recruiting
- Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
-
Montpellier, France
- +7 more
Dec 19, 2022
Melanoma Trial in Worldwide (Atezolizumab, Atezolizumab Placebo, Cobimetinib)
Carotid Plaque Burden in Philadelphia Negative
Recruiting
- Myeloproliferative Neoplasm
-
Sohag, EgyptFaculty of Medicine
Aug 14, 2023
Melanoma Trial in Worldwide (Dabrafenib, Trametinib, Placebos)
Advanced or Metastatic Solid Tumor, KRAS G12C Mutation Trial in Changsha (BEBT-607Tablets)
Recruiting
- Advanced or Metastatic Solid Tumor
- KRAS G12C Mutation
-
Changsha, Hunan, ChinaXiangya Hospital of Central South University
Nov 2, 2023
Homologous Recombination Repair Pathway Gene Mutation Spectrum
Not yet recruiting
- Breast Cancer
- (no location specified)
Jun 4, 2023
NSCLC Trial in Guangzhou (PLB1001)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Aug 15, 2023
Advanced NSCLC Trial in Jinan (almonertinib)
Recruiting
- Advanced Non-small Cell Lung Cancer
-
Jinan, Shandong, ChinaDegan Lu
Sep 12, 2023
Leptin Receptor Deficiency Obesity Trial in Worldwide (setmelanotide, Placebo)
Completed
- Leptin Receptor Deficiency Obesity
- setmelanotide
- Placebo
-
New York, New York
- +6 more
Jan 26, 2021
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma Trial in
Active, not recruiting
- Locally Advanced Pancreatic Adenocarcinoma
- +4 more
- Biopsy
- +4 more
-
Chicago, Illinois
- +11 more
Jun 28, 2022
Lung Cancer Trial in Boston, Nashville
Active, not recruiting
- Lung Cancer
-
Boston, Massachusetts
- +1 more
Dec 28, 2022
Cystic Fibrosis, Pulmonary Trial in Shanghai (Sweat Test)
Recruiting
- Cystic Fibrosis, Pulmonary
- Sweat Test
-
Shanghai, Shanghai, ChinaShanghai pulmonary hospital
Oct 31, 2022
Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)
Recruiting
- Non-Small Cell Lung Carcinoma
- Capmatinib 150 mg
- Capmatinib 200 mg
-
Guwahati, Assam, India
- +7 more
Dec 19, 2022